UA77145C2 - Extended release dosage formulation - Google Patents

Extended release dosage formulation Download PDF

Info

Publication number: UA77145C2
Authority: UA; Ukraine
Prior art keywords: spheroid; venlafaxine hydrochloride; mixture; coating; core
Prior art date: 1997-11-05

Application number

UA2000063197A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-05

Filing date

1998-03-11

Publication date

2006-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA77145(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-03-11 Application filed by Wyeth Corp filed Critical Wyeth Corp

2006-11-15 Publication of UA77145C2 publication Critical patent/UA77145C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 68
238000013265 extended release Methods 0.000 title abstract description 17
238000009472 formulation Methods 0.000 title abstract description 6
229960002416 venlafaxine hydrochloride Drugs 0.000 claims abstract description 77
QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims abstract description 77
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 42
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 38
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 38
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 38
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 26
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 26
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 26
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 26
238000000576 coating method Methods 0.000 claims description 31
239000011248 coating agent Substances 0.000 claims description 30
239000001856 Ethyl cellulose Substances 0.000 claims description 23
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 23
238000013268 sustained release Methods 0.000 claims description 23
239000012730 sustained-release form Substances 0.000 claims description 23
235000019325 ethyl cellulose Nutrition 0.000 claims description 22
229920001249 ethyl cellulose Polymers 0.000 claims description 22
238000000034 method Methods 0.000 claims description 19
230000002035 prolonged effect Effects 0.000 claims description 14
230000001225 therapeutic effect Effects 0.000 claims description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 6
239000008213 purified water Substances 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 4
229920000609 methyl cellulose Polymers 0.000 claims description 4
239000001923 methylcellulose Substances 0.000 claims description 4
235000010981 methylcellulose Nutrition 0.000 claims description 4
238000012876 topography Methods 0.000 claims 1
239000002552 dosage form Substances 0.000 abstract description 6
206010047700 Vomiting Diseases 0.000 abstract description 3
230000037058 blood plasma level Effects 0.000 abstract description 2
230000001430 anti-depressive effect Effects 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000007916 tablet composition Substances 0.000 abstract 1
239000002775 capsule Substances 0.000 description 24
229940079593 drug Drugs 0.000 description 20
239000003814 drug Substances 0.000 description 20
210000002381 plasma Anatomy 0.000 description 19
229960004688 venlafaxine Drugs 0.000 description 18
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 18
238000004090 dissolution Methods 0.000 description 13
239000012729 immediate-release (IR) formulation Substances 0.000 description 12
239000000243 solution Substances 0.000 description 10
239000007888 film coating Substances 0.000 description 8
238000009501 film coating Methods 0.000 description 8
239000007903 gelatin capsule Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 6
238000011282 treatment Methods 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
-1 for example Substances 0.000 description 4
239000000017 hydrogel Substances 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229920003086 cellulose ether Polymers 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000001125 extrusion Methods 0.000 description 3
229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000008693 nausea Effects 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000007873 sieving Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
HFNCOTSLOKKPHU-UHFFFAOYSA-N cyclohexanol;hydrochloride Chemical compound Cl.OC1CCCCC1 HFNCOTSLOKKPHU-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
239000003000 extruded plastic Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000026781 habituation Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000012728 immediate-release (IR) tablet Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
230000001962 neuropharmacologic effect Effects 0.000 description 1
238000004859 neutralization-reionization mass spectrometry Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000004321 preservation Methods 0.000 description 1
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
239000012088 reference solution Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2000063197A 1997-11-05 1998-03-11 Extended release dosage formulation UA77145C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US96432897A	1997-11-05	1997-11-05
PCT/US1998/023338 WO1999022724A2 (en)	1997-11-05	1998-11-03	Extended release formulation containing venlafaxin

Publications (1)

Publication Number	Publication Date
UA77145C2 true UA77145C2 (en)	2006-11-15

Family

ID=25508423

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000063197A UA77145C2 (en)	1997-11-05	1998-03-11	Extended release dosage formulation

Country Status (39)

Country	Link
EP (1)	EP1028718B1 (id)
JP (1)	JP2001521892A (id)
KR (1)	KR20010031797A (id)
CN (1)	CN1278165A (id)
AR (1)	AR014012A1 (id)
AT (1)	ATE237320T1 (id)
AU (1)	AU747978B2 (id)
BG (1)	BG104397A (id)
BR (1)	BR9813179A (id)
CA (1)	CA2305242A1 (id)
CL (1)	CL2004001705A1 (id)
CO (1)	CO5011060A1 (id)
CZ (1)	CZ20001659A3 (id)
DE (1)	DE69813602T2 (id)
DK (1)	DK1028718T3 (id)
EA (1)	EA200000487A1 (id)
EE (1)	EE04577B1 (id)
ES (1)	ES2196620T3 (id)
GE (1)	GEP20043198B (id)
HK (1)	HK1029056A1 (id)
HR (1)	HRP20000213B1 (id)
HU (1)	HU225238B1 (id)
ID (1)	ID26317A (id)
IL (1)	IL135457A0 (id)
MA (1)	MA24691A1 (id)
NO (1)	NO20002126L (id)
NZ (1)	NZ504460A (id)
PA (1)	PA8462501A1 (id)
PE (1)	PE128699A1 (id)
PL (1)	PL341141A1 (id)
PT (1)	PT1028718E (id)
SK (1)	SK6472000A3 (id)
SV (1)	SV1998000131A (id)
TR (1)	TR200001232T2 (id)
TW (1)	TW555568B (id)
UA (1)	UA77145C2 (id)
UY (2)	UY25234A1 (id)
WO (1)	WO1999022724A2 (id)
ZA (1)	ZA9810081B (id)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1905757A1 (en) *	1999-04-06	2008-04-02	Sepracor Inc.	Derivatives of Venlafaxine and methods of preparing and using the same
JP2003500348A (ja) *	1999-05-20	2003-01-07	エランコーポレーシヨンピーエルシー	多粒子状制御放出選択的セロトニン再吸収阻害剤製剤
IL146462A (en)	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2003050075A1 (en) *	2001-12-05	2003-06-19	Wyeth	Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
AU2002247945A1 (en) *	2001-12-13	2003-06-23	Cadila Healthcare Limited	Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
WO2003055475A1 (en) *	2002-01-03	2003-07-10	Lek Pharmaceutical And Chemical Company D.D.	Controlled release pharmaceutical formulation containing venlafaxine
AU2003221535A1 (en)	2002-03-28	2003-10-13	Synthon B.V.	Venlafaxine besylate
AU2003226751A1 (en)	2002-03-28	2003-10-13	Synthon B.V.	Low water-soluble venlafaxine salts
WO2003082262A2 (en) *	2002-03-28	2003-10-09	Synthon B.V.	Compositions of venlafaxine base
WO2003082261A1 (en) *	2002-03-28	2003-10-09	Synthon B.V.	Extended release venlafaxine formulations
FR2845289B1 (fr)	2002-10-04	2004-12-03	Ethypharm Sa	Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) *	2002-12-24	2009-06-16	Biovail Laboratories Inc.	Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) *	2003-10-28	2005-11-10	Bioplanta Arzneimittel Gmbh	Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) *	2003-03-28	2005-02-01	Sandoz Ag	Venlafaxine compositions
PT1502587E (pt) *	2003-07-30	2007-01-31	Pharmathen Sa	Formulação de libertação prolongada para cloridrato de venlafaxina
HUP0303382A2 (hu) *	2003-10-10	2005-08-29	EGIS Gyógyszergyár Rt.	Venlafaxin-hidroklorid-tartalmú pelletek
PT1711169E (pt)	2004-02-04	2007-07-23	Alembic Ltd	Minicomprimidos revestidos de libertação prolongada de cloridrato de venlafaxina.
US7776358B2 (en)	2004-07-22	2010-08-17	Synthon Ip Inc.	Extended release venlafaxine besylate tablets
CN101453996B (zh) *	2006-04-03	2016-05-11	伊萨·奥迪迪	药物递送组合物
WO2007129329A2 (en) *	2006-05-08	2007-11-15	Jubilant Organosys Limited	Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) *	2012-08-16	2014-01-08	乐普药业股份有限公司	一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) *	2018-04-11	2021-04-30	Ghs Patents Ltd	Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1561204A (en) *	1977-06-01	1980-02-13	Ici Ltd	Sustained release pharmaceutical composition
US6440457B1 (en) *	1993-05-27	2002-08-27	Alza Corporation	Method of administering antidepressant dosage form
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
ZA97976B (en) *	1996-04-05	1997-08-18	Alza Corp	Uniform drug delivery theraphy.

1998
- 1998-03-11 UA UA2000063197A patent/UA77145C2/uk unknown
- 1998-10-30 PA PA19988462501A patent/PA8462501A1/es unknown
- 1998-11-02 MA MA25330A patent/MA24691A1/fr unknown
- 1998-11-03 KR KR1020007004865A patent/KR20010031797A/ko not_active Application Discontinuation
- 1998-11-03 CO CO98064480A patent/CO5011060A1/es unknown
- 1998-11-03 CN CN98810881A patent/CN1278165A/zh active Pending
- 1998-11-03 DE DE69813602T patent/DE69813602T2/de not_active Revoked
- 1998-11-03 EA EA200000487A patent/EA200000487A1/ru unknown
- 1998-11-03 ID IDW20000834A patent/ID26317A/id unknown
- 1998-11-03 JP JP2000518658A patent/JP2001521892A/ja active Pending
- 1998-11-03 TW TW086102797A patent/TW555568B/zh not_active IP Right Cessation
- 1998-11-03 HU HU0004287A patent/HU225238B1/hu not_active IP Right Cessation
- 1998-11-03 CZ CZ20001659A patent/CZ20001659A3/cs unknown
- 1998-11-03 EP EP98956487A patent/EP1028718B1/en not_active Revoked
- 1998-11-03 GE GEAP19985388A patent/GEP20043198B/en unknown
- 1998-11-03 ES ES98956487T patent/ES2196620T3/es not_active Expired - Lifetime
- 1998-11-03 CA CA002305242A patent/CA2305242A1/en not_active Abandoned
- 1998-11-03 NZ NZ504460A patent/NZ504460A/xx unknown
- 1998-11-03 WO PCT/US1998/023338 patent/WO1999022724A2/en not_active Application Discontinuation
- 1998-11-03 PL PL98341141A patent/PL341141A1/xx not_active Application Discontinuation
- 1998-11-03 IL IL13545798A patent/IL135457A0/xx unknown
- 1998-11-03 PT PT98956487T patent/PT1028718E/pt unknown
- 1998-11-03 AU AU13003/99A patent/AU747978B2/en not_active Ceased
- 1998-11-03 BR BR9813179-6A patent/BR9813179A/pt not_active Application Discontinuation
- 1998-11-03 SK SK647-2000A patent/SK6472000A3/sk unknown
- 1998-11-03 DK DK98956487T patent/DK1028718T3/da active
- 1998-11-03 EE EEP200000212A patent/EE04577B1/xx not_active IP Right Cessation
- 1998-11-03 AT AT98956487T patent/ATE237320T1/de not_active IP Right Cessation
- 1998-11-03 TR TR2000/01232T patent/TR200001232T2/xx unknown
- 1998-11-04 SV SV1998000131A patent/SV1998000131A/es not_active Application Discontinuation
- 1998-11-04 AR ARP980105563A patent/AR014012A1/es unknown
- 1998-11-04 PE PE1998001045A patent/PE128699A1/es not_active Application Discontinuation
- 1998-11-04 ZA ZA9810081A patent/ZA9810081B/xx unknown
- 1998-11-05 UY UY25234A patent/UY25234A1/es not_active IP Right Cessation
1999
- 1999-09-03 UY UY25692A patent/UY25692A1/es not_active IP Right Cessation
2000
- 2000-04-13 HR HR20000213A patent/HRP20000213B1/xx not_active IP Right Cessation
- 2000-04-26 NO NO20002126A patent/NO20002126L/no not_active Application Discontinuation
- 2000-05-04 BG BG104397A patent/BG104397A/xx unknown
- 2000-12-21 HK HK00108358A patent/HK1029056A1/xx not_active IP Right Cessation
2004
- 2004-07-06 CL CL200401705A patent/CL2004001705A1/es unknown

Also Published As

Publication number	Publication date
GEP20043198B (en)	2004-03-25
PE128699A1 (es)	2000-01-06
DK1028718T3 (da)	2003-07-28
HUP0004287A2 (hu)	2002-04-29
DE69813602T2 (de)	2003-11-06
HUP0004287A3 (en)	2002-05-28
BR9813179A (pt)	2000-08-22
AR014012A1 (es)	2001-01-31
NZ504460A (en)	2003-01-31
EE200000212A (et)	2001-04-16
AU1300399A (en)	1999-05-24
NO20002126L (no)	2000-05-04
HK1029056A1 (en)	2001-03-23
HRP20000213A2 (en)	2000-12-31
HRP20000213B1 (en)	2004-04-30
NO20002126D0 (no)	2000-04-26
UY25692A1 (es)	2000-03-31
EA200000487A1 (ru)	2000-10-30
CA2305242A1 (en)	1999-05-14
AU747978B2 (en)	2002-05-30
DE69813602D1 (de)	2003-05-22
ID26317A (id)	2000-12-14
PL341141A1 (en)	2001-03-26
CN1278165A (zh)	2000-12-27
EP1028718A2 (en)	2000-08-23
HU225238B1 (en)	2006-08-28
IL135457A0 (en)	2001-05-20
MA24691A1 (fr)	1999-07-01
EE04577B1 (et)	2006-02-15
CO5011060A1 (es)	2001-02-28
SV1998000131A (es)	1999-11-18
ZA9810081B (en)	2000-05-04
PT1028718E (pt)	2003-07-31
TR200001232T2 (tr)	2000-12-21
CL2004001705A1 (es)	2005-06-03
WO1999022724A2 (en)	1999-05-14
UY25234A1 (es)	2000-12-29
PA8462501A1 (es)	2000-05-24
KR20010031797A (ko)	2001-04-16
ATE237320T1 (de)	2003-05-15
WO1999022724A3 (en)	1999-07-22
SK6472000A3 (en)	2000-11-07
JP2001521892A (ja)	2001-11-13
TW555568B (en)	2003-10-01
BG104397A (en)	2001-02-28
ES2196620T3 (es)	2003-12-16
CZ20001659A3 (cs)	2001-10-17
EP1028718B1 (en)	2003-04-16

Publication	Publication Date	Title
RU2176912C2 (ru)	2001-12-20	Композиции длительного высвобождения венлафаксин гидрохлорида, композиция пленочного покрытия, способ обеспечения терапевтически активной концентрации венлафаксина и способ исключения нулевых и пиковых концентраций лекарственного средства
UA77145C2 (en)	2006-11-15	Extended release dosage formulation
US6419958B2 (en)	2002-07-16	Extended release formulation of venlafaxine hydrochloride
DK166478B1 (da)	1993-06-01	Farmaceutisk praeparat med langsom frigoering
SU1706373A3 (ru)	1992-01-15	Способ получени средства с регулируемым высвобождением активного соединени
CZ303275B6 (cs)	2012-07-11	Farmaceutický prostredek
US20030215507A1 (en)	2003-11-20	Extended release formulation
EP1331003B1 (en)	2015-08-26	Extended release formulation containing venlafaxine
US20080124392A1 (en)	2008-05-29	Extended release formulation
MXPA97001873A (en)	1998-07-03	Prolong release formulation
AU6544200A (en)	2001-01-04	Extended release formulation